Skip to content

Current ratio at other companies

Incyte logo
IncyteINCY
3.7×+1.6×
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
5.8×+0.3×
UroGen Pharma logo
UroGen PharmaURGN
4.7×-1.0×
BridgeBio Pharma logo
BridgeBio PharmaBBIO
1.5×-3.0×
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
14×-0.4×
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
5.5×-0.3×

Other financials

Income statement

See full
Operating income-$42.0M-31.9%
Net income-$39.3M-39.6%
EPS (diluted)-$0.64-36.2%

Balance sheet

See full
Cash & equivalents$85.0M-15.7%
Total debt$5.7M-6.9%
Total equity$387.6M+19.8%
Total assets$412.0M+20.0%

Cash flow

See full
Operating cash flow-$32.6M-27.9%
CapEx$88.0K+529%
Free cash flow-$32.7M-28.2%

Valuation

See full
Market cap$1.79B+318%
Enterprise value$1.71B+397%

Returns & leverage

See full
Return on equity-36.9%+21.1pp
Debt / equity0.0×

Where this comes from

Calculated from Tyra Biosciences, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Tyra Biosciences, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tyra Biosciences, Inc.'s current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tyra Biosciences, Inc.'s current ratio?
Tyra Biosciences, Inc. (TYRA) reported current ratio of 20.5× in Q1 2026.
How has Tyra Biosciences, Inc.'s current ratio changed year-over-year?
Tyra Biosciences, Inc.'s current ratio decreased by 10.1% year-over-year, from 22.8× to 20.5×.
What is the long-term trend for Tyra Biosciences, Inc.'s current ratio?
Over 5 years (2020 to 2025), Tyra Biosciences, Inc.'s current ratio has grown at a 12.3% compound annual growth rate (CAGR), from 8.2× to 14.7×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.